Skip to main content

Table 3 Comparison of multivariate competing risk analysis and multivariate Cox regression analysis

From: Specific mortality in patients with diffuse large B-cell lymphoma: a retrospective analysis based on the surveillance, epidemiology, and end results database

Factors

Levels

Competing risk model

Cox proportional risk model

HR (95% CI)

P value

HR (95% CI)

P value

Age

0–20 years (reference)

    

20–39 years

1.39 (0.84–2.31)

0.2000

1.46 (0.88–2.42)

0.1380

40–59 years

2.27 (1.39–3.7)

0.0010*

2.47 (1.52–4.01)

0.0003*

60–79 years

3.94 (2.42–6.41)

< 0.0001*

4.35 (2.68–7.07)

< 0.0001*

80–100 years

6.7 (4.1–10.95)

< 0.0001*

8.01 (4.92–13.04)

< 0.0001*

Ann Arbor stage

Stage I (reference)

    

Stage II

1.44 (1.29–1.6)

< 0.0001*

1.48 (1.33–1.65)

< 0.0001*

Stage III

1.76 (1.57–1.96)

< 0.0001*

1.81 (1.62–2.02)

< 0.0001*

Stage IV

2.42 (2.19–2.68)

< 0.0001*

2.56 (2.32–2.83)

< 0.0001*

B symptoms

No (reference)

    

Yes

1.32 (1.24–1.41)

< 0.0001*

1.33 (1.25–1.42)

< 0.0001*

Chemotherapy

With (reference)

    

Without

1.86 (1.64–2.11)

< 0.0001*

2.28 (2.02–2.57)

< 0.0001*

First primary tumor

No (reference)

    

Yes

0.88 (0.82–0.94)

0.0003*

0.84 (0.78–0.9)

< 0.0001*

Marital status

Divorce (reference)

    

Married

0.87 (0.78–0.96)

0.0074*

0.84 (0.76–0.94)

0.0014*

Other

0.76 (0.64–0.91)

0.0023*

0.77 (0.64–0.91)

0.0033*

Separated

0.96 (0.69–1.34)

0.8100

0.93 (0.68–1.28)

0.6712

Single

0.89 (0.79–1.02)

0.0880

0.91 (0.8–1.03)

0.1367

Widowed

0.96 (0.84–1.09)

0.5000

0.96 (0.85–1.09)

0.5505

Median household income

< $50,000 (reference)

    

> $75,000

0.81 (0.73–0.89)

< 0.0001*

0.79 (0.72–0.87)

< 0.0001*

$50,000–$74,999

0.91 (0.83–0.99)

0.0310*

0.89 (0.82–0.97)

0.0091*

Race

Asian (reference)

    

Black

0.94 (0.81–1.09)

0.4300

0.98 (0.84–1.14)

0.7941

Other

0.55 (0.37–0.83)

0.0041*

0.53 (0.36–0.8)

0.0024*

White

0.81 (0.73–0.9)

0.0001*

0.83 (0.74–0.92)

0.0003*

Radiation

With (reference)

    

Without

1.18 (1.09–1.28)

0.0001*

1.2 (1.1–1.3)

< 0.0001*

Site

Extranodal (reference)

    

Nodal

1.13 (1.05–1.22)

0.0011*

1.13 (1.05–1.21)

0.0010*

Surgery

With (reference)

    

Without

1.36 (1.18–1.56)

< 0.0001*

1.45 (1.27–1.66)

< 0.0001*

The sequence of systemic therapy and surgery

No systemic therapy and/or surgery (reference)

    

Other

2.18 (1.06–4.47)

0.0340*

2.2 (1.09–4.43)

0.0277*

Systemic therapy after surgery

1 (0.87–1.15)

0.9700

1.03 (0.9–1.18)

0.6474

Systemic therapy before surgery

1.4 (0.9–2.17)

0.1400

1.69 (1.12–2.54)

0.0124*

Systemic therapy both before and after surgery

1.28 (0.72–2.27)

0.4000

1.26 (0.69–2.3)

0.4430

Treatment timing

\(\le\) 1 month (reference)

    

> 1 month

0.79 (0.74–0.84)

< 0.0001*

0.78 (0.73–0.83)

< 0.0001*

  1. *P < 0.05
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us